A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)

Study Summary

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response

Interventions

Study Locations

Facility	City	State	Country
City of Hope	Duarte	California	United States
Children's Hospital Los Angeles	Los Angeles	California	United States
H. Lee Moffitt Cancer Center and Research Institute Hospital	Tampa	Florida	United States
Washington University Saint Louis	St Louis	Missouri	United States
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	United States
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	United States
MD Anderson Cancer Center	Houston	Texas	United States
Seattle Children's Hospital	Seattle	Washington	United States
Peter Mac Callum Cancer Institute	Melbourne	Victoria	Australia
Royal Children's Melbourne	Melbourne	Victoria	Australia

Official Trial Information

View on ClinicalTrials.gov